NEO2734 | EP31670 | p300(CBP)/BET Inhibitor | AmBeed-信号通路专用抑制剂

NEO2734 {[allProObj[0].p_purity_real_show]}

货号：A1359463 同义名： EP31670

NEO2734是一种口服的双重 p300/CBP 和 BET 溴结构域抑制剂，IC50 值均小于 30 nM。

NEO2734 化学结构
CAS号：2081072-29-7

NEO2734 3D分子结构
CAS号：2081072-29-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

表观遗传阅读框亚型比较

产品名称	BET ↓ ↑	bromodomain ↓ ↑	BRPF ↓ ↑	CBP/beta-catenin ↓ ↑	p300/CBP ↓ ↑	其他靶点	纯度
MS436	++ BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM						99%+
CPI-203	+++ BRD4, IC50: 37 nM						98+%
GSK1324726A	+++ BRD2, IC50: 31 nM BRD4, IC50: 22 nM						99%+
PFI-1	++ BRD2, IC50: 98 nM BRD4, IC50: 0.22 μM						98%
Apabetalone	+ BD2, IC50: 0.51 μM						99%
(+)-JQ1	+++ BRD4 (2), IC50: 33 nM BRD4 (1), IC50: 77 nM						98%
I-BET151	+ BRD3, IC50: 0.25 μM BRD4, IC50: 0.5 μM						98%
Molibresib	+++ BET proteins, IC50: 35 nM						99%+
I-BRD9	+++ BRD4, pIC50: 5.3 BRD9, pIC50: 7.3						99%+
BI-7273	++++ BRD7, IC50: 117 nM BRD9, IC50: 19 nM						97%
Pelabresib	+++ BRD4-BD1, IC50: 39 nM						98%
ARV-825	+++ BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM						99%+
Birabresib							99%+
BI 2536	+++ BRD4, Kd: 37 nM					c-Myc	99%+
Bromosporine	++ BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM	++++ CECR2, IC50: 17 nM					99%+
XMD8-92	++ BRD4 (1), Kd: 170 nM						99%+
Mivebresib	✔						99%+
BI-9564	++++ BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM	++ CECR2, Kd: 77 nM					98%
AZD5153 6-Hydroxy-2-naphthoic acid	++++ FL-BRD4, IC50: 5 nM						99%+
PLX51107	++++ BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM						99%+
FL-411	+ BRD4(1), IC50: 0.43 μM						99%+
ABBV-744	✔						99%+
dBET6	++++ BRD4, IC50: 14 nM						99%+
dBET1	++++ BRD4, IC50: 20 nM						99%+
MZ1	++++ Brd2(BD2), Kd: 62 nM Brd3(BD2), Kd: 13 nM						99%+
dBET57	+ BRD4_BD1, DC50: 500 nM						99%+
SF2523	+ BRD4, IC50: 241 nM					DNA-PK	99%+
INCB054329	++++ BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM						99%
INCB-057643	✔						99%+
(E/Z)-ZL0420	+++ BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM						99%+
BMS-986158	✔						99%
BRD4 Inhibitor-10	++++ BRD4-BD2, IC50: 41 nM BRD4-BD1, IC50: 5 nM						97%
A1874	✔						99%+
Y06036	++ BRD4 (1), Kd: 82 nM						99%+
Alobresib	✔					NF-κB	95%
ODM-207	✔						98%
GSK778	+++ BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM						97%
SRX3207	+ BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM					Syk	98%
GSK046	+++ BRD3_BD2, IC50: 98 nM BRD4_BD2, IC50: 214 nM						98%
GSK620	✔						97%
Trotabresib	✔						99%
NHWD-870	✔						98%
CFT8634	++++ BRD9, DC50: 3 nM						98%
GSK2801		++ BAZ2A, Kd: 257 nM BAZ2B, Kd: 136 nM					99%+
KG-501		✔					99%+
UNC 669		+ L3MBTL3, IC50: 35 μM L3MBTL4, IC50: 6 μM					99%
PFI-3		+++ SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM					99%+
UNC1215		+++ L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM					99%+
EED226		++ EED, Kd: 82 nM PRC2, Kd: 114 nM					99%+
BRD9539		✔					98%
UNC926		+ L3MBTL1, Kd: 3.9 μM					99%
666-15		++ CREB, IC50: 81 nM					99%+
UNC6852		+ EED, IC50: 247 nM					98%
BAZ1A-IN-1		+ BAZ1A, Kd: 0.52 μM					99%+
PFI-4			++ BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM				99%+
OF-1			++ BRPF1B, Kd: 100 nM BRPF2, Kd: 500 nM				99%+
GSK-5959			++ BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2				99%
GSK6853			++++ BRPF1, pIC50: 8.1				99%+
NI-42			++++ BRPF3, IC50: 260 nM BRPF1, IC50: 48 nM				99%+
E-7386				+++ CBP/beta-catenin, IC50: 0.0484 μM			99%
I-CBP112					++ CBP, Kd: 151 nM p300, Kd: 167 nM		98+%
Histone Acetyltransferase Inhibitor II					+ p300, IC50: 5 μM		98%
C646					+ p300/CBP, Ki: 400 nM		99%+
Anacardic Acid					+ p300/CBP, IC50: 8.5 μM PCAF, IC50: 5 μM		99%+
SGC-CBP30					++++ EP300, IC50: 38 nM CREBBP, IC50: 21 nM		99%+
Nordihydroguaiaretic acid					✔	IGF-1R,HER2	99%+
Curcumin					+ p300, IC50: ~25 μM	Ferroptosis,NF-κB,Nrf2	98%
CPI-637					+++ EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM		99%+
Foscenvivint					✔	β-catenin	99%+
A-485					++ p300 HAT, IC50: 0.06 μM		99%+
GNE-781	+ BRD4(1), IC50: 5100 nM				++++ CBP, IC50: 0.94 nM		99%
NEO2734	+++ BET, IC50: <30 nM				+++ p300/CBP, IC50: <30 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

NEO2734 生物活性

靶点

p300/CBP

p300/CBP, IC50:<30 nM
BET

BET, IC50:<30 nM

描述

NEO2734 (EP31670) is an orally active inhibitor selectively targeting both p300/CBP and BET bromodomains, displaying IC50 values of less than 30 nM for each^[1]. NEO2734 is effective in both SPOP mutant and wild-type prostate cancer^[2].

体内研究

NEO2734 (5, 8, 10 mg/kg, orally) suppresses tumor growth and extends survival in preclinical xenograft models^[1].

体外研究

NEO2734 (1 μM) promotes differentiation and induces G1-phase cell cycle arrest^[1].

NEO2734 (1 μM) quickly triggers squamous differentiation in NMC cell lines, including the expression of the terminal squamous differentiation markers involucrin and keratins^[1].

NEO2734 is effective against both hotspot mutant (F133V) and non-hotspot mutant (Q165P) prostate cancer (PCa) cells in vitro andin vivo^[2].

NEO2734 细胞实验

Cell Line KG1 KN473 IB119 DLBCL cell lines Primary AML cells KG1a MV4;11 THP1 HL60 C4-2 cells DU145 cells SNU-407 NCI-H508 DLD-1 RKO LOVO HCT116 JR588 IB106	Concentration	Treated Time	Description	References
KG1	100 nM	48 hours	NEO2734 significantly downregulated the expression of c-Myc and Bcl2.	Hemasphere. 2021 Jul 8;5(8):e610.
KN473	60 µM	72 hours	Evaluate the antitumor activity of NEO2734 on UPS cells, results showed over 40% of viable cells remained at higher doses	Transl Oncol. 2025 Feb;52:102236.
IB119	25 µM	72 hours	Evaluate the antitumor activity of NEO2734 on UPS cells, results showed over 40% of viable cells remained at higher doses	Transl Oncol. 2025 Feb;52:102236.
DLBCL cell lines	157 nM (median IC50)	72 hours	Evaluate the antiproliferative activity of NEO2734 in DLBCL cell lines, showing higher sensitivity in ABC-DLBCL than GCB-DLBCL	Blood Adv. 2020 Sep 8;4(17):4124-4135.
Primary AML cells	6-175 nM	4 days	NEO2734 significantly eliminated primary AML cells and reduced cell survival by inducing apoptosis.	Hemasphere. 2021 Jul 8;5(8):e610.
KG1a	27-125 nM	96 hours	NEO2734 significantly reduced the viability of AML cell lines and induced apoptosis.	Hemasphere. 2021 Jul 8;5(8):e610.
MV4;11	100 nM	2 and 5 hours	NEO2734 significantly downregulated the expression of c-Myc but had minimal effect on Bcl2, though it reduced MCL1 expression.	Hemasphere. 2021 Jul 8;5(8):e610.
THP1	100 nM	2 and 5 hours	NEO2734 significantly downregulated the expression of c-Myc and Bcl2.	Hemasphere. 2021 Jul 8;5(8):e610.
HL60	27-125 nM	96 hours	NEO2734 significantly reduced the viability of AML cell lines and induced apoptosis.	Hemasphere. 2021 Jul 8;5(8):e610.
C4-2 cells	2 μM	72 hours	To evaluate the inhibitory effect of NEO2734 on the growth of SPOP mutant C4-2 cells. Results showed that F133V mutant cells were resistant to JQ1 but sensitive to NEO2734.	EMBO Mol Med. 2019 Nov 7;11(11):e10659.
DU145 cells	2 μM	72 hours	To evaluate the inhibitory effect of NEO2734 on the growth of SPOP Q165P mutant DU145 cells. Results showed that NEO2734 significantly inhibited cell growth, with superior effect compared to the combination of JQ1 and CPI-637.	EMBO Mol Med. 2019 Nov 7;11(11):e10659.
SNU-407	0.036 µM	72 hours	To evaluate the inhibitory effect of NEO2734 on the growth of SNU-407 cells, results showed that NEO2734 significantly inhibited cell growth with an IC50 of 0.036 µM.	Front Oncol. 2022 Oct 12;12:1018775.
NCI-H508	0.059 µM	72 hours	To evaluate the inhibitory effect of NEO2734 on the growth of NCI-H508 cells, results showed that NEO2734 significantly inhibited cell growth with an IC50 of 0.059 µM.	Front Oncol. 2022 Oct 12;12:1018775.
DLD-1	10 µM	48 hours	To evaluate the effect of NEO2734 on apoptosis in DLD-1 cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.	Front Oncol. 2022 Oct 12;12:1018775.
RKO	10 µM	48 hours	To evaluate the effect of NEO2734 on apoptosis in RKO cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.	Front Oncol. 2022 Oct 12;12:1018775.
LOVO	1 µM	48 hours	To evaluate the effect of NEO2734 on apoptosis in LOVO cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.	Front Oncol. 2022 Oct 12;12:1018775.
HCT116	10 µM	24 hours	To evaluate the effect of NEO2734 on apoptosis in HCT116 cells, results showed that NEO2734 significantly increased the proportion of Annexin V-positive cells, indicating induction of apoptosis.	Front Oncol. 2022 Oct 12;12:1018775.
JR588	0.2863 µM	72 hours	Evaluate the antitumor activity of NEO2734 on UPS cells, results showed NEO2734 decreased cell viability through regulation of E2F targets and cell cycle	Transl Oncol. 2025 Feb;52:102236.
IB106	1.088 µM	72 hours	Evaluate the antitumor activity of NEO2734 on UPS cells, results showed NEO2734 decreased cell viability through regulation of E2F targets and cell cycle	Transl Oncol. 2025 Feb;52:102236.

Cell Line

Concentration

Treated Time

Description

References

KG1

100 nM

48 hours

NEO2734 significantly downregulated the expression of c-Myc and Bcl2.

Hemasphere. 2021 Jul 8;5(8):e610.

KN473

60 µM

72 hours

Evaluate the antitumor activity of NEO2734 on UPS cells, results showed over 40% of viable cells remained at higher doses

Transl Oncol. 2025 Feb;52:102236.

IB119

25 µM

72 hours

Evaluate the antitumor activity of NEO2734 on UPS cells, results showed over 40% of viable cells remained at higher doses

Transl Oncol. 2025 Feb;52:102236.

DLBCL cell lines

157 nM (median IC50)

72 hours

Evaluate the antiproliferative activity of NEO2734 in DLBCL cell lines, showing higher sensitivity in ABC-DLBCL than GCB-DLBCL

Blood Adv. 2020 Sep 8;4(17):4124-4135.

Primary AML cells

6-175 nM

4 days

NEO2734 significantly eliminated primary AML cells and reduced cell survival by inducing apoptosis.

Hemasphere. 2021 Jul 8;5(8):e610.

KG1a

27-125 nM

96 hours

NEO2734 significantly reduced the viability of AML cell lines and induced apoptosis.

Hemasphere. 2021 Jul 8;5(8):e610.

MV4;11

100 nM

2 and 5 hours

NEO2734 significantly downregulated the expression of c-Myc but had minimal effect on Bcl2, though it reduced MCL1 expression.

Hemasphere. 2021 Jul 8;5(8):e610.

THP1

100 nM

2 and 5 hours

NEO2734 significantly downregulated the expression of c-Myc and Bcl2.

Hemasphere. 2021 Jul 8;5(8):e610.

HL60

27-125 nM

96 hours

NEO2734 significantly reduced the viability of AML cell lines and induced apoptosis.

Hemasphere. 2021 Jul 8;5(8):e610.

C4-2 cells

2 μM

72 hours

To evaluate the inhibitory effect of NEO2734 on the growth of SPOP mutant C4-2 cells. Results showed that F133V mutant cells were resistant to JQ1 but sensitive to NEO2734.

EMBO Mol Med. 2019 Nov 7;11(11):e10659.

DU145 cells

2 μM

72 hours

To evaluate the inhibitory effect of NEO2734 on the growth of SPOP Q165P mutant DU145 cells. Results showed that NEO2734 significantly inhibited cell growth, with superior effect compared to the combination of JQ1 and CPI-637.

EMBO Mol Med. 2019 Nov 7;11(11):e10659.

SNU-407

0.036 µM

72 hours

To evaluate the inhibitory effect of NEO2734 on the growth of SNU-407 cells, results showed that NEO2734 significantly inhibited cell growth with an IC50 of 0.036 µM.

Front Oncol. 2022 Oct 12;12:1018775.

NCI-H508

0.059 µM

72 hours

To evaluate the inhibitory effect of NEO2734 on the growth of NCI-H508 cells, results showed that NEO2734 significantly inhibited cell growth with an IC50 of 0.059 µM.

Front Oncol. 2022 Oct 12;12:1018775.

DLD-1

10 µM

48 hours

To evaluate the effect of NEO2734 on apoptosis in DLD-1 cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.

Front Oncol. 2022 Oct 12;12:1018775.

RKO

10 µM

48 hours

To evaluate the effect of NEO2734 on apoptosis in RKO cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.

Front Oncol. 2022 Oct 12;12:1018775.

LOVO

1 µM

48 hours

To evaluate the effect of NEO2734 on apoptosis in LOVO cells, results showed that NEO2734 induced cleavage of caspase-3, indicating activation of apoptosis.

Front Oncol. 2022 Oct 12;12:1018775.

HCT116

10 µM

24 hours

To evaluate the effect of NEO2734 on apoptosis in HCT116 cells, results showed that NEO2734 significantly increased the proportion of Annexin V-positive cells, indicating induction of apoptosis.

Front Oncol. 2022 Oct 12;12:1018775.

JR588

0.2863 µM

72 hours

Evaluate the antitumor activity of NEO2734 on UPS cells, results showed NEO2734 decreased cell viability through regulation of E2F targets and cell cycle

Transl Oncol. 2025 Feb;52:102236.

IB106

1.088 µM

72 hours

Evaluate the antitumor activity of NEO2734 on UPS cells, results showed NEO2734 decreased cell viability through regulation of E2F targets and cell cycle

Transl Oncol. 2025 Feb;52:102236.

NEO2734 动物实验

Species SCID (CB17) mice SCID mice Nude mice Rag2-/- γc-/- mice Mice NOD-SCID mice	Animal Model MV4;11 tumor xenograft model SPOP Q165P mutant PDX model HCT116 xenograft model JR588 and KN473 PDX models 22Rv1 xenograft model TMD8 xenograft model	Administration	Dosage	Frequency	Description	References
SCID (CB17) mice	MV4;11 tumor xenograft model	Oral	10 mg/kg	Once daily for 11 consecutive days	NEO2734 significantly inhibited tumor growth of MV4;11 cells.	Hemasphere. 2021 Jul 8;5(8):e610.
SCID mice	SPOP Q165P mutant PDX model	Intraperitoneal injection	30 mg/kg	5 days per week for 3 consecutive weeks	To evaluate the inhibitory effect of NEO2734 on the growth of SPOP Q165P mutant PDX tumors. Results showed that NEO2734 significantly suppressed tumor growth, with superior effect compared to the combination of JQ1 and CPI-637.	EMBO Mol Med. 2019 Nov 7;11(11):e10659.
Nude mice	HCT116 xenograft model	Oral gavage	30 mg/kg	Administered on days 1, 5, and 9, for a total of 9 days	To evaluate the antitumor effect of NEO2734 in the HCT116 xenograft model, results showed that NEO2734 significantly inhibited tumor growth and induced tumor cell apoptosis.	Front Oncol. 2022 Oct 12;12:1018775.
Rag2-/- γc-/- mice	JR588 and KN473 PDX models	Oral	10 mg/kg	Once daily (5 days-on/2 days-off)	Evaluate the antitumor activity of NEO2734 in vivo, results showed NEO2734 significantly inhibited tumor growth in JR588 PDX model	Transl Oncol. 2025 Feb;52:102236.
Mice	22Rv1 xenograft model	Intraperitoneal injection	10 mg/kg	5 days per week for 21 days	Evaluate the effect of NEO2734 alone or in combination with ENZ on 22Rv1 xenograft tumor growth, results showed combination therapy significantly inhibited tumor growth	Cancer Res. 2023 Oct 2;83(19):3192-3204
NOD-SCID mice	TMD8 xenograft model	Oral	10 mg/kg	Once daily, 6 days per week	Evaluate the antitumor activity of NEO2734 in a DLBCL xenograft model, showing significant tumor growth inhibition	Blood Adv. 2020 Sep 8;4(17):4124-4135.

Species

SCID (CB17) mice SCID mice Nude mice Rag2-/- γc-/- mice Mice NOD-SCID mice

Animal Model

MV4;11 tumor xenograft model SPOP Q165P mutant PDX model HCT116 xenograft model JR588 and KN473 PDX models 22Rv1 xenograft model TMD8 xenograft model

Administration

Dosage

Frequency

Description

References

SCID (CB17) mice

MV4;11 tumor xenograft model

Oral

10 mg/kg

Once daily for 11 consecutive days

NEO2734 significantly inhibited tumor growth of MV4;11 cells.

Hemasphere. 2021 Jul 8;5(8):e610.

SCID mice

SPOP Q165P mutant PDX model

Intraperitoneal injection

30 mg/kg

5 days per week for 3 consecutive weeks

To evaluate the inhibitory effect of NEO2734 on the growth of SPOP Q165P mutant PDX tumors. Results showed that NEO2734 significantly suppressed tumor growth, with superior effect compared to the combination of JQ1 and CPI-637.

EMBO Mol Med. 2019 Nov 7;11(11):e10659.

Nude mice

HCT116 xenograft model

Oral gavage

30 mg/kg

Administered on days 1, 5, and 9, for a total of 9 days

To evaluate the antitumor effect of NEO2734 in the HCT116 xenograft model, results showed that NEO2734 significantly inhibited tumor growth and induced tumor cell apoptosis.

Front Oncol. 2022 Oct 12;12:1018775.

Rag2-/- γc-/- mice

JR588 and KN473 PDX models

Oral

10 mg/kg

Once daily (5 days-on/2 days-off)

Evaluate the antitumor activity of NEO2734 in vivo, results showed NEO2734 significantly inhibited tumor growth in JR588 PDX model

Transl Oncol. 2025 Feb;52:102236.

Mice

22Rv1 xenograft model

Intraperitoneal injection

10 mg/kg

5 days per week for 21 days

Evaluate the effect of NEO2734 alone or in combination with ENZ on 22Rv1 xenograft tumor growth, results showed combination therapy significantly inhibited tumor growth

Cancer Res. 2023 Oct 2;83(19):3192-3204

NOD-SCID mice

TMD8 xenograft model

Oral

10 mg/kg

Once daily, 6 days per week

Evaluate the antitumor activity of NEO2734 in a DLBCL xenograft model, showing significant tumor growth inhibition

Blood Adv. 2020 Sep 8;4(17):4124-4135.

NEO2734 参考文献

NEO2734 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.48mL

2.30mL

1.15mL

22.97mL

4.59mL

2.30mL

NEO2734 技术信息

CAS号	2081072-29-7
分子式	C₂₂H₂₄F₃N₃O₃
分子量	435.44
SMILES Code	O=C1C(C)=CC(C2=CC=C3N=C(C4CCOCC4)N(CCOC(F)(F)F)C3=C2)=CN1C
MDL No.	MFCD32857168

别名	EP31670
运输	蓝冰
InChI Key	KPWWFNXRLAAREN-UHFFFAOYSA-N
Pubchem ID	126582741

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(241.14 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

NEO2734 {[allProObj[0].p_purity_real_show]}

NEO2734 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

NEO2734 质控信息

NEO2734 生物活性

NEO2734 细胞实验

NEO2734 动物实验

NEO2734 参考文献

NEO2734 实验方案

NEO2734 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	p300/CBP p300/CBP, IC50:<30 nM BET BET, IC50:<30 nM
描述	NEO2734 (EP31670) is an orally active inhibitor selectively targeting both p300/CBP and BET bromodomains, displaying IC50 values of less than 30 nM for each^[1]. NEO2734 is effective in both SPOP mutant and wild-type prostate cancer^[2].
体内研究	NEO2734 (5, 8, 10 mg/kg, orally) suppresses tumor growth and extends survival in preclinical xenograft models^[1].
体外研究	NEO2734 (1 μM) promotes differentiation and induces G1-phase cell cycle arrest^[1]. NEO2734 (1 μM) quickly triggers squamous differentiation in NMC cell lines, including the expression of the terminal squamous differentiation markers involucrin and keratins^[1]. NEO2734 is effective against both hotspot mutant (F133V) and non-hotspot mutant (Q165P) prostate cancer (PCa) cells in vitro andin vivo^[2].

NEO2734 {[allProObj[0].p_purity_real_show]}

NEO2734 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

NEO2734 质控信息

NEO2734 生物活性

NEO2734 细胞实验

NEO2734 动物实验

NEO2734 参考文献

NEO2734 实验方案

NEO2734 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

NEO2734 纯度/质量文件产品仅供科研